Anti-Angiogenic Therapy: Adapting Strategies to Overcome Resistant Tumors

被引：23

作者：

Mitchell, Dianne C. ^{[2
]}

Bryan, Brad A. ^{[1
]}

机构：

[1] Worcester State Coll, Dept Biol, Ghosh Sci & Technol Ctr, Worcester, MA 01602 USA

[2] Acceleron Pharmaceut, Cambridge, MA USA

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2010年 / 111卷 / 03期

关键词：

VASCULAR ENDOTHELIAL GROWTH FACTOR; AVASTIN; ANGIOGENESIS; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; PROGENITOR CELLS; ANTITUMOR-ACTIVITY; VEGF RECEPTORS; HUMAN-MELANOMA; TGF-BETA; FACTOR-I; EXPRESSION; BEVACIZUMAB;

D O I：

10.1002/jcb.22764

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Healthy cells, as well as benign and malignant tumors, depend upon the body's blood supply to bring in oxygen and nutrients and carry away waste products. Using this property against tumors, anti-angiogenic therapy targets the tumor vasculature with the aim of starving the tumor, and has demonstrated exceptional clinical efficacy against a number of tumors. This review discusses the current state of knowledge regarding anti-angiogenic therapies presently available to patients, and garners from both preclinical and clinical literature the benefits and side effects associated with anti-angiogenic therapies, the unfortunate mechanisms of acquired resistance to these novel therapeutics, and highlights promising next generation anti-angiogenics that may overcome the limitations encountered with first generation therapies. J. Cell. Biochem. 111: 543-553, 2010. (c) 2010 Wiley-Liss, Inc.

引用

页码：543 / 553

页数：11

共 93 条

[1] Murine lewis lung carcinoma-derived endothelium expresses markers of endothelial activation and requires tumor-specific extracellular matrix in vitro
Allport, JR
Weissleder, R
[J]. NEOPLASIA, 2003, 5 (03): : 205 - 217
[2] Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors
Annabi, B
Naud, E
Lee, YT
Eliopoulos, N
Galipeau, J
[J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (06) : 1146 - 1158
[3] Barleon B, 1997, CANCER RES, V57, P5421
[4] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Batchelor, Tracy T.
Sorensen, A. Gregory
di Tomaso, Emmanuelle
Zhang, Wei-Ting
Duda, Dan G.
Cohen, Kenneth S.
Kozak, Kevin R.
Cahill, Daniel P.
Chen, Poe-Jou
Zhu, Mingwang
Ancukiewicz, Marek
Mrugala, Maciej M.
Plotkin, Scott
Drappatz, Jan
Louis, David N.
Ivy, Percy
Scadden, David T.
Benner, Thomas
Loeffler, Jay S.
Wen, Patrick Y.
Jain, Rakesh K.
[J]. CANCER CELL, 2007, 11 (01) : 83 - 95
[5] Regulation of vascular permeability by vascular endothelial growth factors
Bates, DO
Harper, SJ
[J]. VASCULAR PHARMACOLOGY, 2002, 39 (4-5) : 225 - 237
[6] Modes of resistance to anti-angiogenic therapy
Bergers, Gabriele
Hanahan, Douglas
[J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 592 - 603
[7] VEGF and VEGF receptors are differentially expressed in chondrocytes
Bluteau, Gilles
Julien, Marion
Magne, David
Mallein-Genin, Frederic
Weiss, Pierre
Daculsi, Guy
Guicheux, Jerome
[J]. BONE, 2007, 40 (03) : 568 - 576
[8] Coordinated vascular endothelial growth factor expression and signaling during skeletal myogenic differentiation
Bryan, Brad A.
Walshe, Tony E.
Mitchell, Dianne C.
Havumaki, Josh S.
Saint-Geniez, Magali
Maharaj, Arindel S.
Maldonado, Angel E.
D'Amore, Patricia A.
[J]. MOLECULAR BIOLOGY OF THE CELL, 2008, 19 (03) : 994 - 1006
[9] Altered angiogenesis and survival in human tumor-derived endothelial cells
Bussolati, B
Deambrosis, I
Russo, S
Deregibus, MC
Camussi, G
[J]. FASEB JOURNAL, 2003, 17 (06) : 1159 - +
[10] Identification of a tumor-initiating stem cell population in human renal carcinomas
Bussolati, Benedetta
Bruno, Stefania
Grange, Cristina
Ferrando, Ugo
Camussi, Giovanni
[J]. FASEB JOURNAL, 2008, 22 (10) : 3696 - 3705

← 1 2 3 4 5 6 7 8 9 10 →